{"id":34873,"date":"2018-08-24T11:32:26","date_gmt":"2018-08-24T11:32:26","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=34873"},"modified":"2018-08-24T15:52:47","modified_gmt":"2018-08-24T15:52:47","slug":"hiv-vaccine-from-janssen-moves-into-new-phase-3-study","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/34873","title":{"rendered":"Janssen HIV vaccine: update from APPROACH and largescale efficacy study"},"content":{"rendered":"

\"\"Simon Collins, HIV i-Base<\/strong><\/p>\n

As an HIV vaccine is likely to be a critical component of an HIV cure, ongoing results presented by Frank Tomaka and colleagues from Janssen were encouraging for showing improved immune responses to a promising new preventative HIV vaccine. [1]<\/strong><\/p>\n

These were from the phase 2 APPROACH study first presented last year and published in the Lancet in the weeks before AIDS 2018. [2]<\/p>\n

This analysis included longer follow-up. All participants generated immune responses that were higher than levels that protected monkeys in animal studies and that were maintained for more than a year and five-year follow-up is planned.<\/p>\n

Based on these results a large efficacy study called Imbokodo is already ongoing. Although this new study was referred to several times as phase 3 at the conference, the trial listing is as phase 2. [3, 4]<\/p>\n

A second related presentation also suggested that a shorter 24-week vaccine schedule might be just as effective as the 48 week schedule currently used in the Imbokodo study. [5]<\/p>\n

References<\/p>\n

    \n
  1. Tomaka F et al. Long-term data from APPROACH: Phase 1\/2a randomized, double-blind, placebo-controlled study evaluating safety\/tolerability and immunogenicity of vaccine regimens using combinations of Ad26.Mos.HIV, MVA-mosaic and gp140 envelope protein. AIDS 2018, 23\u00ac\u201327 July 2018, Amsterdam. Oral abstract TUAA0104.
    \nhttp:\/\/programme.aids2018.org\/Abstract\/Abstract\/10764<\/a> (abstract and slides)<\/li>\n
  2. Barouch DK et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). The Lancet 392(10143): 232\u2013243. (06 July 2018)
    \n    https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(18)31364-3\/fulltext<\/a><\/li>\n
  3. clinicaltrials.gov. A study to assess the efficacy of a heterologous prime\/boost vaccine regimen of Ad26.Mos4.HIV and aluminum phosphate-adjuvanted clade C gp140 in preventing HIV-1 infection in women in sub-saharan Africa.
    \n    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03060629<\/a><\/li>\n
  4. Imbokodo website.
    \n    https:\/\/www.imbokodo.org.za<\/a><\/li>\n
  5. Stephenson K et al. HPX1002\/IPCAVD010: A randomized controlled trial evaluating the safety and immunogenicity of shorter and simpler vaccine schedules using Ad26.Mos.HIV combined with gp140 Env protein. AIDS 2018, 23\u00ac\u201327 July 2018, Amsterdam. Oral abstract TUAA0104.
    \n    http:\/\/programme.aids2018.org\/Abstract\/Abstract\/11441<\/a> (abstract and slides)<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base As an HIV vaccine is likely to be a critical component of an HIV cure, ongoing results presented by Frank Tomaka and colleagues from Janssen were encouraging for showing improved immune responses to a promising new …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,10,20],"tags":[255],"class_list":["post-34873","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-transmission-and-prevention","category-cure-research","tag-world-aids-22-amsterdam-2018"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/34873","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=34873"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/34873\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=34873"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=34873"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=34873"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}